Details for New Drug Application (NDA): 204325
✉ Email this page to a colleague
The generic ingredient in ADZENYS ER is amphetamine. There are fifty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amphetamine profile page.
Summary for 204325
Tradename: | ADZENYS ER |
Applicant: | Neos Theraps Inc |
Ingredient: | amphetamine |
Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 204325
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION, EXTENDED RELEASE;ORAL | Strength | EQ 1.25MG BASE/ML | ||||
Approval Date: | Sep 15, 2017 | TE: | RLD: | Yes | |||||
Patent: | 8,709,491 | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 9,017,731 | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 9,265,737 | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription